Panbela Therapeutics, Inc. Common Stock
PBLA
PBLA was delisted on the 6th of March, 2024.
15 hedge funds and large institutions have $854K invested in Panbela Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 7 closing their positions.
2,371% more capital invested
Capital invested by funds: $34.5K → $854K (+$819K)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
50% more funds holding
Funds holding: 10 → 15 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$689K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$638K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$574K |
| 4 |
ACM
Altium Capital Management
New York
|
+$542K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$264K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4K |
| 2 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$1.66K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.51K |
| 4 |
OFG
Oxford Financial Group
Carmel,
Indiana
|
-$1.47K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.46K |
PBLA Hedge Fund Activity: Q1 2023 in Review
15 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q1 2023, worth a combined $854K — up 2,371% from $34.5K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PBLA positions and 7 closed out — a net gain of 5 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $689K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $4K sold.
- 15 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q1 2023, up from 10 in Q4 2022.
- Funds reported $854K of Panbela Therapeutics, Inc. Common Stock stock for Q1 2023, up 2,371% quarter-over-quarter.
- 12 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q1 2023 and 7 closed out, a net change of +5 holders.
- The largest Panbela Therapeutics, Inc. Common Stock buyer in Q1 2023 was Sabby Management, an estimated $689K added.
- The largest Panbela Therapeutics, Inc. Common Stock seller in Q1 2023 was Renaissance Technologies, an estimated $4K sold.
Based on aggregated 13F filings for Q1 2023.